NasdaqCM:MLTXBiotechs
MoonLake Immunotherapeutics (MLTX) On Phase 3 Data While A 6x P B Valuation Looks Pricey
MoonLake Immunotherapeutics (MLTX) has become a focus for many investors after strong one-year Phase 3 VELA data for sonelokimab in hidradenitis suppurativa and a planned Biologics License Application filing by the end of September.
See our latest analysis for MoonLake Immunotherapeutics.
That clinical update has come alongside a sharp move in MoonLake Immunotherapeutics’ share price, with a 7-day share price return of 11.80% and a 30-day share price return of 16.66%. However, the 1-year...